Skip to content

EBIT at other companies

Guardant Health logo
Guardant HealthGH
Natera, Inc. logo
Natera, Inc.NTRA
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Revvity logo
RevvityRVTY
Labcorp Holdings logo
Labcorp HoldingsLH
Quest Diagnostics logo
Quest DiagnosticsDGX

Other financials

Income statement

See full
Revenue$139.1M+21.5%
Gross profit$101.2M+27.2%
Operating income$22.6M+680%
Net income$28.7M+307%
EPS (diluted)$0.35+289%

Balance sheet

See full
Cash & equivalents$264.8M+41.0%
Total debt$39.3M-22.1%
Total equity$1.3B+12.5%
Total assets$1.4B+9.2%

Cash flow

See full
Operating cash flow$35.2M+557%
CapEx$3.0M+62.8%
Free cash flow$32.3M+810%

Valuation

See full
Market cap$4.29B+10.7%

Profitability

See full
Gross margin70.9%+2.9pp
Operating margin14.3%+9.2pp
Net margin16.2%+9.1pp
FCF margin28.7%+11.7pp

Returns & leverage

See full
Return on equity6.9%+4.1pp
Debt / equity0.0×
Current ratio9.3×+4.2×

Where this comes from

Calculated from Veracyte’s reported figures.

Plus components not separately reported this period.

The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veracyte's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Veracyte's EBIT?
Veracyte (VCYT) reported EBIT of $22.65M in Q1 2026.
How has Veracyte's EBIT changed year-over-year?
Veracyte's EBIT increased by 679.8% year-over-year, from $2.9M to $22.65M.
What is the long-term trend for Veracyte's EBIT?
Over 4 years (2021 to 2025), Veracyte's EBIT has grown at a -8.4% compound annual growth rate (CAGR), from -$81.9M to $57.78M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.